Abstract
Objective To identify the symptoms and unmet needs of people with Parkinson’s Disease and characterize Phase 2-3 and Phase 3 clinical trials.
Methods We surveyed people with Parkinson’s Disease to determine their symptoms, pharmacological and non-pharmacological treatments, side effects, and insufficiently managed or unmanaged symptoms, and wishes for Parkinson’s Disease research. We identified clinical trials through clinicaltrials.gov.
Results Twenty-eight people with Parkinson’s Disease completed the study (22 survey, six interview), and 38 clinical trials were characterized. The majority of participants’ desires for clinical development and outcomes of clinical trials characterized targeted motor symptoms.
Conclusions Despite numerous therapeutics available, motor symptoms continue to be a top priority for people with Parkinson’s Disease and focus for drug development.
All relevant ethical guidelines have been followed, all necessary IRB and/or ethics committee approvals have been obtained, all necessary patient/participant consent has been obtained and the appropriate institutional forms archived.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the University of Rochester Research Subjects Review Board, study number STUDY00004151
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
